

## Results of the Combined General Shareholders' Meeting held on June 10, 2016

Romainville, June 10, 2016, 6pm – BIOPHYTIS (Alternext Paris: ALBPS), biotechnology company specialized in the development of drug candidates to treat aging diseases, announces the approval of all resolutions (with the exception of resolution 15) submitted to shareholders during the Combined General shareholders' Meeting of June 10, 2016, including one authorizing the Company's listing on a U.S. stock market in the next 12 months.

The shareholders present or represented taking part in the vote altogether owned 3,693,075 shares and 3,693,075 voting rights, i.e. 59.59% of voting rights.

The shareholders approved by a very large majority all of the resolutions (with the exception of resolution 15), including one authorizing the Company's listing on a U.S. stock market in the next 12 months.

Other key resolutions approved were:

- The social and consolidated accounts for fiscal year 2015
- The allocation of profit for the fiscal year ended December 31, 2015
- The delegations of financial authority and authorisations granted to the Board of Directors

Full results of votes on resolutions will be available on the Company's website from June 13, 2016, in the « Investors / Regulated information » section.

\*\*\*

### About BIOPHYTIS

Biophytis SA ([www.biophytis.com](http://www.biophytis.com)), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS ; ISIN: FR0012816825).



### Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on BIOPHYTIS' website ([www.biophytis.com](http://www.biophytis.com)).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.

**BIOPHYTIS**  
**Stanislas VEILLET**  
CEO  
contact@biophytis.com  
Tel : +33 (0) 1 41 83 66 00

**Milestones**  
**Media & Investor relations**  
**Bruno ARABIAN**  
barabian@milestones.fr  
Tel : +33 (0) 1 83 62 34 84  
Mob : +33 (0) 6 87 88 47 26

**LifeSci Advisors**  
**Chris MAGGOS**  
Managing Director, Europe  
chris@lifesciadvisors.com  
Tel : +41 79 367 6254

**Citigate Dewe Rogerson**  
**International media**  
**Laurence BAULT/Antoine DENRY**  
[Laurence.bault@citiagte.fr](mailto:Laurence.bault@citiagte.fr)/[adenry@citigate.fr](mailto:adenry@citigate.fr)  
Tel : +33 (0)1 53 32 84 78  
Mob : +33(0)6 64 12 53 61